Epidemiology, Diagnosis and Management of Penile Cancer: Results from the Spanish National Registry of Penile Cancer.
cancer
epidemiology
incidence
penile cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 01 2023
19 01 2023
Historique:
received:
22
12
2022
revised:
11
01
2023
accepted:
17
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Penile cancer (PC) is a rare malignancy with an overall incidence in Europe of 1/100,000 males/year. In Europe, few studies report the epidemiology, risk factors, clinical presentation, and treatment of PC. The aim of this study is to present an updated outlook on the aforementioned factors of PC in Spain. A multicentric, retrospective, observational epidemiological study was designed, and patients with a new diagnosis of PC in 2015 were included. Patients were anonymously identified from the Register of Specialized Care Activity of the Ministry of Health of Spain. All Spanish hospitals recruiting patients in 2015 were invited to participate in the present study. We have followed a descriptive narration of the observed data. Continuous and categorical data were reported by median (p25th-p75th range) and absolute and relative frequencies, respectively. The incidence map shows differences between Spanish regions. The incidence of PC in Spain in 2015 was 2.55/100,000 males per year. A total of 586 patients were identified, and 228 patients from 61 hospitals were included in the analysis. A total of 54/61 (88.5%) centers reported ≤ 5 new cases. The patients accessed the urologist for visually-assessed penile lesions (60.5%), mainly localized in the glans (63.6%). Local hygiene, smoking habits, sexual habits, HPV exposure, and history of penile lesions were reported in 48.2%, 59.6%, 25%, 13.2%, and 69.7%. HPV-positive lesions were 18.1% (28.6% HPV-16). The majority of PC was squamous carcinoma (95.2%). PC was ≥cT2 in 45.2% (103/228) cases. At final pathology, PC was ≥pT2 in 51% of patients and ≥pN1 in 17% of cases. The most common local treatment was partial penectomy (46.9% cases). A total of 47/55 (85.5%) inguinal lymphadenectomies were open. Patients with ≥pN1 disease were treated with chemotherapy in 12/39 (40.8%) of cases. PC incidence is relatively high in Spain compared to other European countries. The risk factors for PC are usually misreported. The diagnosis and management of PC are suboptimal, encouraging the identification of referral centers for PC management.
Identifiants
pubmed: 36765574
pii: cancers15030616
doi: 10.3390/cancers15030616
pmc: PMC9913503
pii:
doi:
Types de publication
Journal Article
Langues
eng
Investigateurs
Alejandro García Viña
Jaume Pelegrí Gabarró
Ana Plata Bello
Rubén Campanario Pérez
Juan Manuel Corral Molina
Juan Braulio García Ramos
Mariano Rosselló Gayá
Enrique Gómez Gómez
Ignacio Puche Sanz
Antonio Tienza Fernández
Ane Miren Iturregui Del Pozo
Pablo Jimenez Marrero
María Esther Gordo Flores
Rafael Galisteo Moya
Isabel Lacasa Viscasillas
Francisco Clar
Pedro Morales Jiménez
Marcos Antonio Lloret Durá
Jorge Subirá Ríos
Daniel Sánchez Zalabardo
Sara Martínez Breijo
Ana Daroca Fernández
Pastora Beardo Villar
Samuel Méndez Ramírez
Carlos Salvador Lacambra
Miguel Rodrigo Aliaga
Victoria Muñoz Guillermo
Diego Fernando Bravo López
Miguel Ángel Bonillo García
Pedro Jesús Fernández Anguita
Miguel Efrén Jiménez Romero
Víctor Escobal Tamayo
Eduardo Albers Acosta
Cristóbal Moreno Alarcón
Antonio Guijarro Espadas
Gloria María Calvo González
Ramiro García Ruiz
Ana María Autrán Gómez
Andrés Ponce Campuzano
Jesús Calleja Escudero
Edwin Ariel Grinard De León
José Emilio Hernández Sánchez
Andrés Rodríguez Alonso
Francisco Javier Sanz Sacristán
José María Prats De Puig
Ernesto Sánchez Sánchez
Víctor Gonzalvo Pérez
Francisco Javier Ramada Benlloch
Álvaro Amancio Fernández Alcalde
Yumaira Elena Hernández Martínez
Francisco José Jiménez Penick
Juan Andrés González Dacal
María Asunción Costa Martínez
Références
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
World J Clin Pediatr. 2017 Feb 8;6(1):89-102
pubmed: 28224100
Nat Rev Dis Primers. 2021 Feb 11;7(1):11
pubmed: 33574340
Transl Androl Urol. 2017 Oct;6(5):785-790
pubmed: 29184774
Cancer Causes Control. 2022 Jan;33(1):117-123
pubmed: 34698994
Eur Urol Focus. 2022 Dec 22;:
pubmed: 36566099
Urol Oncol. 2018 Apr;36(4):141-146
pubmed: 28882673
Curr Opin Urol. 2019 Mar;29(2):145-149
pubmed: 30562185
AIDS. 2018 Nov 13;32(17):2573-2581
pubmed: 30096075
IARC Sci Publ. 1997;(138):65-176
pubmed: 9353664
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530343
Eur Urol Focus. 2022 Sep;8(5):1318-1322
pubmed: 34903488
World J Urol. 2013 Aug;31(4):861-7
pubmed: 22116602
Cancer Causes Control. 2012 Feb;23(2):273-80
pubmed: 22101453
Cancers (Basel). 2022 Dec 19;14(24):
pubmed: 36551733
Int J STD AIDS. 2023 Jan 11;:9564624221148622
pubmed: 36630307
Cancer Causes Control. 2009 May;20(4):449-57
pubmed: 19082746
Eur Urol Oncol. 2021 Feb;4(1):121-123
pubmed: 32943378
Int Braz J Urol. 2008 Sep-Oct;34(5):587-91; discussion 591-3
pubmed: 18986562
Nat Rev Urol. 2022 Apr;19(4):231-239
pubmed: 34937881
Urol Oncol. 2019 Apr;37(4):295.e1-295.e8
pubmed: 30595462
World J Urol. 2009 Apr;27(2):141-50
pubmed: 18607597
Cancer Causes Control. 2013 Dec;24(12):2169-76
pubmed: 24101363
Curr Probl Cancer. 2015 May-Jun;39(3):126-36
pubmed: 26076979
Sex Transm Dis. 2022 May 1;49(5):368-376
pubmed: 35082241
Urology. 2010 Aug;76(2 Suppl 1):S2-6
pubmed: 20691882
Cancer Epidemiol. 2017 Oct;50(Pt A):125-131
pubmed: 28898817
Infect Agent Cancer. 2021 Mar 31;16(1):22
pubmed: 33789689
Urology. 2017 Nov;109:140-144
pubmed: 28818536